MX2015011195A - La leucina y el acido nicotinico reducen los niveles de lipidos. - Google Patents

La leucina y el acido nicotinico reducen los niveles de lipidos.

Info

Publication number
MX2015011195A
MX2015011195A MX2015011195A MX2015011195A MX2015011195A MX 2015011195 A MX2015011195 A MX 2015011195A MX 2015011195 A MX2015011195 A MX 2015011195A MX 2015011195 A MX2015011195 A MX 2015011195A MX 2015011195 A MX2015011195 A MX 2015011195A
Authority
MX
Mexico
Prior art keywords
leucine
nicotinic acid
lipids
reduce levels
acid reduce
Prior art date
Application number
MX2015011195A
Other languages
English (en)
Spanish (es)
Inventor
Michael Zemel
Antje Bruckbauer
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Publication of MX2015011195A publication Critical patent/MX2015011195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
MX2015011195A 2013-03-15 2014-03-13 La leucina y el acido nicotinico reducen los niveles de lipidos. MX2015011195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800363P 2013-03-15 2013-03-15
PCT/US2014/026816 WO2014152016A1 (en) 2013-03-15 2014-03-13 Leucine and nicotinic acid reduces lipid levels

Publications (1)

Publication Number Publication Date
MX2015011195A true MX2015011195A (es) 2016-03-11

Family

ID=51581094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011195A MX2015011195A (es) 2013-03-15 2014-03-13 La leucina y el acido nicotinico reducen los niveles de lipidos.

Country Status (16)

Country Link
US (5) US9585876B2 (enExample)
EP (1) EP2968333B1 (enExample)
JP (2) JP6550370B2 (enExample)
KR (1) KR20150130455A (enExample)
CN (1) CN105228627B (enExample)
AU (1) AU2014236687A1 (enExample)
BR (1) BR112015023310A2 (enExample)
CA (1) CA2902879C (enExample)
HK (1) HK1219660A1 (enExample)
IL (1) IL240762B (enExample)
MX (1) MX2015011195A (enExample)
PH (1) PH12015502033A1 (enExample)
RU (1) RU2015143836A (enExample)
SG (1) SG11201507046UA (enExample)
WO (1) WO2014152016A1 (enExample)
ZA (4) ZA201506481B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016049236A1 (en) * 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
KR102426320B1 (ko) 2015-03-16 2022-07-29 크로마덱스 아이엔씨. 니코틴산 리보사이드 또는 니코틴아미드 리보사이드 조성물, 이의 환원 유도체, 및 이의 용도
US11013678B2 (en) 2015-06-29 2021-05-25 The Procter & Gamble Company Multi-component skin care product
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
WO2018017726A1 (en) * 2016-07-19 2018-01-25 Winterfield Roland W Methods and compositions for alleviating myopathy
EP3528801B1 (en) * 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
CN120383644A (zh) 2016-11-11 2025-07-29 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
AU2017367092B2 (en) 2016-11-29 2022-11-03 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
US20210177875A1 (en) * 2017-12-01 2021-06-17 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
CA3086535A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
WO2019133815A1 (en) * 2017-12-28 2019-07-04 Kansas State University Research Foundation Nicotinamide riboside treatments of domesticated meat animals
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
US11547693B2 (en) * 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN116019780B (zh) * 2021-10-26 2024-09-24 成都拂尔医药科技有限公司 一种双黄纳米颗粒及其制备与应用

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
EP0873754B1 (en) 1996-01-09 2003-07-30 Riken Amino acid compositions
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0862863B9 (en) 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
JP2002513795A (ja) 1998-05-04 2002-05-14 ヨハネス ケーゼル アンドレアス モノマー、オリゴマーおよびポリマーのクネベナーゲル縮合生成物
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
AU765909C (en) 1998-12-17 2004-09-23 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
AU7596100A (en) 1999-09-21 2001-04-24 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
CA2399319A1 (en) 2000-01-25 2001-08-16 Nathan D. Hamilton Nutritional supplements for aged pets
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
WO2005029242A2 (en) 2000-06-16 2005-03-31 Bodymedia, Inc. System for monitoring and managing body weight and other physiological conditions including iterative and personalized planning, intervention and reporting capability
US7285090B2 (en) 2000-06-16 2007-10-23 Bodymedia, Inc. Apparatus for detecting, receiving, deriving and displaying human physiological and contextual information
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
WO2002052951A1 (en) 2000-12-29 2002-07-11 Martin Francis Gannon An animal food product
JP2004519241A (ja) 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
EP1525323B1 (en) 2001-11-09 2015-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1beta, a novel pgc-1 homologue and uses therefor
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
CA2483464C (en) 2002-05-17 2011-12-20 Duke University Method for treating obesity
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
NZ542280A (en) 2003-03-13 2008-08-29 Vector Usa Inc A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
PL377614A1 (pl) 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
WO2004100968A2 (en) 2003-05-14 2004-11-25 Indus Biotech Pvt. Ltd. A synergistic composition for the treatment of diabetes mellitus
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
EP1667579A4 (en) 2003-09-12 2008-06-11 Bodymedia Inc METHOD AND DEVICE FOR MEASURING CARDIAC PARAMETERS
CN100577027C (zh) 2003-11-03 2010-01-06 希尔氏宠物营养品公司 涂覆的宠物食品组合物
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
WO2005049006A1 (ja) 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
AU2004294986B2 (en) 2003-11-26 2010-09-09 Hill's Pet Nutrition, Inc. Method to reduce stool odor of companion animals
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1762234A4 (en) 2004-06-28 2010-05-05 Kao Corp AMPK AKTIVATOR
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006057073A1 (ja) 2004-11-29 2006-06-01 Toyo Shinyaku Co., Ltd. 運動能力向上組成物
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
BRPI0606736A2 (pt) 2005-02-11 2009-07-21 Argenta Discovery Ltd combinação de compostos e esteróides de metilxantina para tratar doenças respiratórias crÈnicas
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
JP2008535790A (ja) 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CN101175501B (zh) 2005-05-13 2012-03-21 雀巢技术公司 由植物物种生产葡糖胺
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
JP2009500357A (ja) * 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278504B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
US20070190171A1 (en) 2005-12-02 2007-08-16 Yamka Ryan M Methods for Altering Stool Quality and/or Stool Frequency
BRPI0706448A2 (pt) 2006-01-10 2011-03-29 Hills Pet Nutrition Inc método, composição e kit para promover perda de gordura em um animal adulto, meio para comunicar informação sobre ou instruções para usar uma dieta, e, uso de lisina
KR20080108487A (ko) 2006-02-28 2008-12-15 트르스티스 오브 보스톤 유니버시티 대사 조절인자 및 그의 용도
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
WO2007128461A1 (en) 2006-05-10 2007-11-15 Dsm Ip Assets B.V. Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
BRPI0806774A2 (pt) 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
US20080319786A1 (en) 2007-02-16 2008-12-25 Stivoric John M Publishing and insurance applications of lifeotypes
CA2678807C (en) 2007-02-23 2012-07-17 Hill's Pet Nutrition, Inc. Compositions and methods for controlling the weight of animals
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
JPWO2008143182A1 (ja) 2007-05-17 2010-08-05 株式会社カネカ 甘草ポリフェノールを含有する組成物
US20100204204A1 (en) 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
JP5550077B2 (ja) 2007-09-07 2014-07-16 ナイキ インターナショナル リミテッド 運動機能性を有する装着可能な装置アセンブリ
EP2214698A2 (en) 2007-10-23 2010-08-11 President and Fellows of Harvard College Use of compounds activating sirt-3 for mimicking exercise
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
AU2008345571B2 (en) 2007-12-21 2011-10-13 Hill's Pet Nutrition, Inc. Pet food composition
US8716249B2 (en) * 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MY158994A (en) 2008-02-04 2016-11-30 Mercury Therapeutics Inc Ampk modulators
CN106021913B (zh) 2008-03-03 2019-08-09 耐克创新有限合伙公司 交互式运动设备系统及方法
BRPI0908718A2 (pt) 2008-03-17 2019-09-24 Procter & Gamble sistema de dosagem personalizável pelo usuário
JP5645809B2 (ja) 2008-04-02 2014-12-24 ナイキ イノベイト セー． フェー． 運動用機能を有するウェアラブルデバイスアセンブリ
KR20110039249A (ko) 2008-07-07 2011-04-15 모치다 세이야쿠 가부시키가이샤 지질 이상증의 개선 또는 치료약
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
CN102300569A (zh) 2008-08-15 2011-12-28 雀巢产品技术援助有限公司 促进能量代谢的方法
CA2745376A1 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2425303B1 (en) 2009-04-26 2019-01-16 NIKE Innovate C.V. Gps features and functionality in an athletic watch system
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
EP2451295A1 (en) 2009-07-21 2012-05-16 Hill's Pet Nutrition, Inc. Companion animal nutrition system
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2477620A1 (en) 2009-09-18 2012-07-25 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes with a combination of fucoxanthin and punicic acid
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
AU2010336985B2 (en) 2009-12-29 2013-09-19 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
MX340938B (es) 2010-01-06 2016-08-01 Nestec Sa Regimenes dieteticos utiles para imitar la restriccion calorica.
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US8663716B2 (en) 2010-04-28 2014-03-04 Nihon Pharmaceutical Co., Ltd. Composition for treatment of aesthenopia
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
AU2012204162B2 (en) 2011-01-07 2017-04-20 Anji Pharmaceuticals Inc. Chemosensory receptor ligand-based therapies
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
AU2012299126B2 (en) * 2011-08-19 2016-05-26 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
WO2014152016A1 (en) 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
WO2015053379A1 (en) 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.

Also Published As

Publication number Publication date
ZA201705790B (en) 2018-12-19
US20170000780A1 (en) 2017-01-05
ZA201805629B (en) 2019-11-27
US20180214421A1 (en) 2018-08-02
CN105228627B (zh) 2018-07-13
US20160008329A1 (en) 2016-01-14
ZA201606052B (en) 2018-05-30
EP2968333B1 (en) 2022-01-12
IL240762B (en) 2018-11-29
SG11201507046UA (en) 2015-10-29
AU2014236687A1 (en) 2015-09-10
US9585876B2 (en) 2017-03-07
CN105228627A (zh) 2016-01-06
US20170340615A1 (en) 2017-11-30
US9408834B2 (en) 2016-08-09
EP2968333A4 (en) 2016-11-02
CA2902879A1 (en) 2014-09-25
KR20150130455A (ko) 2015-11-23
JP2016516040A (ja) 2016-06-02
PH12015502033A1 (en) 2016-01-18
US9707213B2 (en) 2017-07-18
ZA201506481B (en) 2017-08-30
US9895357B2 (en) 2018-02-20
HK1219660A1 (zh) 2017-04-13
IL240762A0 (en) 2015-10-29
JP2019065049A (ja) 2019-04-25
BR112015023310A2 (pt) 2017-07-18
RU2015143836A (ru) 2017-04-27
US20150056274A1 (en) 2015-02-26
JP6550370B2 (ja) 2019-07-24
EP2968333A1 (en) 2016-01-20
CA2902879C (en) 2023-09-26
WO2014152016A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
MX2015011195A (es) La leucina y el acido nicotinico reducen los niveles de lipidos.
CL2017003404A1 (es) Compuestos antibacterianos
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
MX2018000511A (es) Derivados de fenoximetilo.
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
CR20170594A (es) Moduladores de receptor nuclear
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CL2017000792A1 (es) Derivados del ácido borónico
DK2904910T3 (da) Anvendelse af kastanjetanninekstrakt som antioxidant, antimikrobielt tilsætningsstof og til at reducere nitrosaminer og mykotoksiner
MX387972B (es) Métodos para inhibir la conversión de colina en trimetilamina (tma).
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
SG10201406938SA (en) Laser Spike Annealing Using Fiber Lasers
EA201500931A1 (ru) Производные пиридин-4-ила
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
CR20160083A (es) Compuestos con actividad pesticida
CO6910192A2 (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de pi3kbeta y el inhibidor de la vía de map, incluídos los inhibidores de mek y raf